9. Late Spring '08... GTCB makes MAA to FDA for DIC/Sepsis indication. FDA indicates EU trial info can be used as part of trial support.
10. Annual report shows revenue for '07 was $45,000,000.00 and current revenue streams suggest $100,000,000.00 for '08.
11. Late Summer '08... Dr. Cox discusses in the latest quarterly report why he thought the stockholders had rejected JNJ's bid of $15.75. He indicated a new bid was forthcoming, but did say by who.